Coherus Biosciences Inc (CHRS) was Initiated by Robert W. Baird to “Outperform” and the brokerage firm has set the Price Target at $40. Robert W. Baird advised their investors in a research report released on Oct 19, 2016.
Many Wall Street Analysts have commented on Coherus Biosciences Inc. Maxim Group Initiated Coherus Biosciences Inc on Sep 7, 2016 to “Buy”, Price Target of the shares are set at $43.Citigroup Initiated Coherus Biosciences Inc on Jul 27, 2016 to “Buy”, Price Target of the shares are set at $36.
Coherus Biosciences Inc closed down -0.26 points or -0.91% at $28.18 with 2,85,210 shares getting traded on Friday. Post opening the session at $28.69, the shares hit an intraday low of $28.11 and an intraday high of $28.98 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Oct 5, 2016, Alan C. Herman (Chief Scientific Officer) sold 11,333 shares at $25.86 per share price. According to the SEC, on Sep 28, 2016, Jean-frederic Viret (Chief Financial Officer) sold 3,900 shares at $29.89 per share price. On Sep 22, 2016, Dennis M Lanfear (President and CEO) sold 4,060 shares at $31.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.